Nektar Therapeutics (NKTR) Earnings Date, Estimates & Call Transcripts $23.06 +1.31 (+6.02%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$23.06 +0.00 (+0.00%) As of 08/8/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Nektar Therapeutics Earnings Summary Nektar Therapeutics announced Q2 2025 earnings on August 7, 2025, reporting an EPS of -$2.95, which topped analysts' consensus estimates of -$3.13 by $0.18. Quarterly revenue was reported to be $11.18 million, above analyst estimates of $9.42 million. With a trailing EPS of -$9.60, Nektar Therapeutics' earnings are expected to decrease next year, from ($0.72) to ($0.80) per share. Latest Q2 Earnings DateAug. 7EstimatedConsensus EPS (Aug. 7) -$3.13 Actual EPS (Aug. 7) -$2.95 Beat By $0.18 Actual Revenue (Aug. 7) $11.18MQ2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)Powered by Get Nektar Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nektar Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataNKTR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NKTR Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Nektar Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20254-$3.15-$2.25-$2.70Q2 20254-$3.43-$2.68-$2.99Q3 20254-$2.89-$2.58-$2.76Q4 20254-$3.06-$2.40-$2.74 FY 2025 16 -$12.53 -$9.91 -$11.18 Q1 20263-$3.03-$2.55-$2.86Q2 20263-$3.59-$2.70-$3.22Q3 20263-$4.00-$2.85-$3.30Q4 20263-$4.10-$2.85-$3.37 FY 2026 12 -$14.72 -$10.95 -$12.76 Q1 20271-$3.92-$3.92-$3.92Q2 20271-$4.46-$4.46-$4.46 Nektar Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025-$3.13-$2.95+$0.18-$2.95$9.42M$11.18M5/8/2025Q1 2025-$2.70-$3.30 -$0.60-$0.24$15.61M$10.46M3/12/2025Q4 2024-$2.70$2.25+$4.95$0.03$36.65M$29.18M11/7/2024Q3 2024-$3.45-$2.70+$0.75-$0.18$15.54M$24.12M8/8/2024Q2 2024-$3.15-$3.75 -$0.60-$0.25$17.24M$23.49M5/9/2024Q1 2024-$3.15-$2.70+$0.45-$0.17$14.91M$21.64M3/4/2024Q4 2023-$3.15-$3.30 -$0.15-$0.22$17.09M$23.89M11/7/2023Q3 2023-$2.70-$2.85 -$0.15-$0.14$20.68M$24.14M Nektar Therapeutics Earnings - Frequently Asked Questions When did Nektar Therapeutics announce their last quarterly earnings? Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earning data on Thursday, August 7, 2025. Learn more on NKTR's earnings history. Did Nektar Therapeutics beat their earnings estimates last quarter? In the previous quarter, Nektar Therapeutics (NASDAQ:NKTR) reported ($2.95) earnings per share (EPS) to beat the analysts' consensus estimate of ($3.13) by $0.18. Learn more on analysts' earnings estimate vs. NKTR's actual earnings. How can I listen to Nektar Therapeutics' earnings conference call? The conference call for Nektar Therapeutics' latest earnings report can be listened to online. Listen to Conference Call How can I read Nektar Therapeutics' conference call transcript? The conference call transcript for Nektar Therapeutics' latest earnings report can be read online. Read Transcript How much revenue does Nektar Therapeutics generate each year? Nektar Therapeutics (NASDAQ:NKTR) has a recorded annual revenue of $98.43 million. How much profit does Nektar Therapeutics generate each year? Nektar Therapeutics (NASDAQ:NKTR) has a recorded net income of -$118.96 million. NKTR has generated -$9.60 earnings per share over the last four quarters. What is Nektar Therapeutics' EPS forecast for next year? Nektar Therapeutics' earnings are expected to decrease from ($0.72) per share to ($0.80) per share in the next year. More Earnings Resources from MarketBeat Related Companies PCRX Earnings Date OMER Earnings Date ASMB Earnings Date CPIX Earnings Date LLY Earnings Date JNJ Earnings Date ABBV Earnings Date MRK Earnings Date PFE Earnings Date BMY Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Airbnb Beats Earnings, But the Growth Story Is Losing AltitudeDutch Bros Just Flipped the Script With a Massive Earnings BeatIs Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?Constellation Energy’s Earnings Beat Signals a New EraRealty Income Rallies Post-Earnings Miss—Here’s What Drove ItDon't Mix the Signal for Noise in Super Micro Computer's EarningsWhy Monolithic Power's Earnings and Guidance Ignited a Rally This page (NASDAQ:NKTR) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKTR Stock Alerts